Lactate dehydrogenase in dermatology practice

Livesey, Amy; Garty, F; Shipman, A. R.; Shipman, Kate E.

doi:10.1111/ced.14134

Cited by 21 publications

(12 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the literature, these findings are associated with poorer prognoses. 5,[63][64][65] At diagnosis, 62.4% had early-stage and 37.6% had advanced-stage disease. The literature shows frequencies of early-stage between 78.3 and 92.8% and advanced-stage between 7.2 and 21.8%.…”

Section: According To the Who-eortc Classification Mf Correspondsmentioning

confidence: 99%

Characteristics and outcomes of 727 patients with mycosis fungoides and Sézary syndrome from a Brazilian cohort

Miyashiro

Sanches

2021

Int J Dermatology

View full text Add to dashboard Cite

Background Mycosis fungoides (MF) and S ezary syndrome (SS) are the most prevalent cutaneous lymphomas. They were not described in a large Brazilian cohort yet. We aimed, with this single-center, retrospective cohort analysis, to describe the characteristics and outcomes of MF/SS in a tertiary public health service in Brazil. Methods MF/SS patients evaluated at the University of São Paulo Medical School between 1989 and 2018 were included. Data were collected at diagnosis. Demographic, clinical, histopathological, immunopathological, molecular, laboratory, and follow-up data were analyzed.Results Among 727 patients, 92.6% (673) were diagnosed with MF, 7.4% (54) with SS. There were 51.2% (372) of males, 48.8% (355) of females. The median age was 51.8 years; it was higher in erythrodermic MF (60.2) and SS (60.9). Among MF, 41.8% (281) had classic MF, 4.9% (33) folliculotropic MF, 1.8% (12) granulomatous slack skin, and 0.3% (2) pagetoid reticulosis. Common subtypes included erythrodermic (14.1%, 95), hypopigmented (10.8%, 73), and poikilodermatous MF (10.8%, 73). Extracutaneous involvement was rare. Five, 10, 20, and 30-year overall survival rates were 97.3%, 92.4%, 82.6%, and 82.6% for early-stage, and 58.6%, 42.7%, 20.8%, and 15.4% for advancedstage disease, respectively. After multivariate analysis, SS diagnosis, folliculotropic MF, erythrodermic MF, clinical stage, age (≥60 years), increased lactate dehydrogenase, and large cell transformation conferred poorer prognosis. ConclusionsWe observed a higher percentage of hypopigmented MF compared to the literature, and demographic (older age) and prognostic (poorer prognosis) similarities between erythrodermic MF and SS, suggesting a possible relationship between these erythrodermic lymphomas. Factors associated with a poorer prognosis were compatible with the literature. European Organisation for Research and Treatment of Cancer (EORTC) classification of cutaneous lymphomas, MF is divided into classic MF (CMF), folliculotropic MF (FMF), pagetoid reticulosis (PR), and granulomatous slack skin (GSS). 2 Other clinicopathologic subtypes include erythrodermic (EMF), hypopigmented (HMF), poikilodermatous (PMF), granulomatous, papular, hyperpigmented, ichthyosiform, syringotropic, purpuric, interstitial, pustular, bullous, verrucous, and psoriasiform MF. 3 MF is an indolent disorder, and extracutaneous dissemination is rare. 1,4,5 SS presents with erythroderma, lymphadenopathy, and malignant cells in the blood. 1,6,7 Geographical variation in MF/SS characteristics is known. We aimed to analyze demographic, clinical, histopathological, immunopathological, molecular, laboratory, and follow-up characteristics of MF/SS patients in a Brazilian tertiary public health service. MethodsThis study, a single-center, retrospective cohort analysis, was approved by the local Institutional Review Board and followed the declaration of Helsinki. Patients with MF/SS evaluated at the University of São Paulo Medical School between 1989 and 2018 were included. Data were collected at diagn...

show abstract

Section: According To the Who-eortc Classification Mf Correspondsmentioning

confidence: 99%

Characteristics and outcomes of 727 patients with mycosis fungoides and Sézary syndrome from a Brazilian cohort

Miyashiro

Sanches

2021

Int J Dermatology

View full text Add to dashboard Cite

show abstract

“…Lactate dehydrogenase (LDH) is a stable intracellular enzyme that locates in the cytosol, but it may be released once cells are damaged. 37 LDH leakage was measured in different platelet formulations and only PL + thrombin resulted in a dramatical decrease of the LDH content (Fig. 2F).…”

Section: Papermentioning

confidence: 98%

Glucose-decorated engineering platelets for active and precise tumor-targeted drug delivery

et al. 2023

View full text Add to dashboard Cite

show abstract

“…However, the risk of future cancer among patients with pruritus is not yet established; studies assessing this association have been limited by cross-sectional designs, small sample sizes, and limited follow-up periods . Furthermore, the evaluation of patients with pruritus for cancer involves measuring serum lactate dehydrogenase (LDH), a nonspecific marker of cell turnover, as LDH level is elevated in multiple cancers . However, the diagnostic utility of LDH level in patients with pruritus remains unclear.…”

Section: Introductionmentioning

confidence: 99%

“…[4][5][6][7] Furthermore, the evaluation of patients with pruritus for cancer involves measuring serum lactate dehydrogenase (LDH), a nonspecific marker of cell turnover, as LDH level is elevated in multiple cancers. 8 However, the diagnostic utility of LDH level in patients with pruritus remains unclear. This study assesses the risk of developing hematologic cancer in patients presenting with undifferentiated pruritus, and the utility of serum LDH level as a prognostic marker for cancer in patients with pruritus.…”

mentioning

confidence: 99%

Risk of Hematologic Cancer in Patients With Undifferentiated Pruritus

et al. 2022

View full text Add to dashboard Cite

IMPORTANCEAlthough pruritus is common in patients with hematologic cancers, it is unknown whether patients with undifferentiated pruritus have higher risk of developing hematologic cancer. Furthermore, it is unclear whether serum lactate dehydrogenase (LDH) level, commonly ordered for cancer workup, has diagnostic utility in patients with pruritus.OBJECTIVE To assess the risk of hematologic cancer and the diagnostic utility of LDH level in patients with undifferentiated pruritus. DESIGN, SETTING, AND PARTICIPANTSThis retrospective population-level cohort analysis was conducted using the TriNetX Research Network, a global health records database encompassing more than 69 million patients, from 2002 to 2020. The study included 327 502 eligible patients diagnosed with unspecified pruritus, excluding those with existing chronic pruritic dermatoses or systemic diseases known to cause pruritus, along with 327 502 matched controls.EXPOSURES Development of hematologic cancer within 1 year, 5 years, and 10 years following unspecified pruritus diagnosis.MAIN OUTCOMES AND MEASURES Primary study outcomes were 1-year, 5-year, and 10-year relative risks (RRs) for development of 9 hematologic cancers in patients with pruritus compared with control patients. Secondary outcomes were 1-year, 5-year, and 10-year RRs for any hematologic cancer at different LDH cutoffs (250 U/L and 500 U/L). RESULTSAfter matching, the pruritus and control cohorts each had 327 502 patients (68.1% female patients; 0.4% American Indian or Alaska Native patients; 3.5% Asian patients; 22.2% Black patients; 0.1% Native Hawaiian or Pacific Islander patients; 59.3% White patients; mean [SD] age, 42.2 [22] years). Patients with pruritus had increased 1-year risk of Hodgkin lymphoma (

show abstract

Lactate dehydrogenase in dermatology practice

Cited by 21 publications

References 18 publications

Characteristics and outcomes of 727 patients with mycosis fungoides and Sézary syndrome from a Brazilian cohort

Characteristics and outcomes of 727 patients with mycosis fungoides and Sézary syndrome from a Brazilian cohort

Glucose-decorated engineering platelets for active and precise tumor-targeted drug delivery

Risk of Hematologic Cancer in Patients With Undifferentiated Pruritus

Contact Info

Product

Resources

About